Abstract
Currently recommended antiretrovirals consist of a variety of agents from different drug classes. Differences in mechanism of action result in unique combinations that allow for additive interactions and synergy, leading to increased therapeutic success. However, overlapping toxicities place patients at risk of increased adverse effects such as hepatotoxicity and endocrine abnormalities. A summary of the pharmacological and pharmacokinetic considerations is given in Table 3.1 for currently available nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, integrase inhibitors, and pharmacokinetic enhancers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lexi-comp (2015) Drug information handbook, 24th edn. Lexi-comp, Inc, Hudson
Piliero PJ (2004) Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 37(Suppl 1):S2–S12
Tran JQ, Gerber JG, Kerr BM (2001) Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 40(3):207–226
Smith PF, DiCenzo R, Morse GD (2001) Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 40(12):893–905
Scholler-Gyure M, Kakuda TN, Raoof A, De Smedt G, Hoetelmans RMW (2009) Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet 48(9):561–574
Le Tiec C, Barrail A, Goujard C, Taburet A (2005) Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 44(10):1035–1050
Flexner C (1998) HIV-protease inhibitors. N Eng J Med 338(18):1281–1293
Abel S, Back DJ, Vourvahis M (2009) Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 14(5):607–618
Cottrell ML, Hadzic T, Kashuba AD (2013) Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 52(11):981–994
Ramanathan S, Mathias AA, German P, Kearney BP (2011) Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 50(4):229–244
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Wilby, K.J., Kiang, T.K.L., Ensom, M.H.H. (2016). Pharmacology and Pharmacokinetic Properties of Available Antiretrovirals. In: Kiang, T., Wilby, K., Ensom, M. (eds) Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs. Adis, Singapore. https://doi.org/10.1007/978-981-10-2113-8_3
Download citation
DOI: https://doi.org/10.1007/978-981-10-2113-8_3
Published:
Publisher Name: Adis, Singapore
Print ISBN: 978-981-10-2112-1
Online ISBN: 978-981-10-2113-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)